Apr 15 |
RVPH: Update to Brilaroxazine Safety vs. Efficacy Comparison – Adding RECOVER Data
|
Mar 28 |
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
|
Mar 26 |
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
|
Mar 11 |
Reviva to Present at the UBS Virtual CNS Day
|
Mar 7 |
Reviva to Present at the 36th Annual ROTH Conference
|
Feb 20 |
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
|
Feb 6 |
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
|
Feb 2 |
Reviva Pharmaceuticals files for $200M mixed securities shelf
|
Jan 25 |
Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference
|
Jan 23 |
Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
|